Profile data is unavailable for this security.
About the company
Perrigo Company plc is a provider of over the counter (OTC) health and wellness solutions that are designed to enhance individual well-being. Its segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises of its consumer self-care business in the United States and Canada. It primarily provides its customers self-care products that are sold and marketed under the customer's own brands and/or exclusive brands. The CSCI segment comprises of its consumer self-care business outside of the United States and Canada, primarily in Europe and Australia. These products are developed, manufactured, marketed, and distributed by the Company. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, and Nutrition. Its primary branded products are sold under brand names Compeed, Dr. Fresh, Firefly, Good Sense, Mederma, Nasonex, Solpadeine, Coldrex, and Physiomer, among others.
- Revenue in USD (TTM)4.34bn
- Net income in USD-164.70m
- Incorporated2013
- Employees8.38k
- LocationPerrigo Company PLCThe Sharp BuildingHogan Place, Dublin 2DUBLIN D02 TY74IrelandIRL
- Phone+353 17094000
- Websitehttps://www.perrigo.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Twist Bioscience Corp | 347.68m | -191.15m | 2.26bn | 923.00 | -- | 5.14 | -- | 6.51 | -3.26 | -3.26 | 5.90 | 7.35 | 0.5355 | 7.23 | 8.09 | 376,684.70 | -29.44 | -28.50 | -33.07 | -31.56 | 46.70 | 39.40 | -54.98 | -93.82 | 4.24 | -- | 0.00 | -- | 27.69 | 41.91 | -2.01 | -- | -19.22 | -- |
| Ligand Pharmaceuticals Inc | 181.49m | -132.62m | 2.45bn | 68.00 | -- | 3.08 | -- | 13.49 | -7.12 | -7.12 | 9.73 | 41.27 | 0.1995 | 0.7255 | 5.42 | 2,668,941.00 | -14.58 | 1.82 | -15.22 | 1.92 | 92.81 | 82.57 | -73.07 | 10.30 | 5.02 | -0.2833 | 0.00003 | 0.00 | 27.28 | 6.80 | -107.49 | -- | -6.53 | -- |
| Apellis Pharmaceuticals Inc | 775.84m | -223.68m | 2.50bn | 705.00 | -- | 15.24 | -- | 3.23 | -1.79 | -1.79 | 6.23 | 1.31 | 0.9466 | 1.08 | 3.08 | 1,100,482.00 | -27.29 | -61.31 | -35.92 | -76.53 | 83.00 | 86.49 | -28.83 | -157.26 | 3.62 | -5.43 | 0.7341 | -- | 97.02 | -- | 62.57 | -- | -24.96 | -- |
| Organon & Co | 6.29bn | 750.00m | 2.55bn | 10.00k | 3.40 | 4.67 | 2.44 | 0.4052 | 2.89 | 2.89 | 24.23 | 2.10 | 0.5026 | 2.05 | 4.19 | 629,400.00 | 5.99 | 11.52 | 7.54 | 14.94 | 57.18 | 62.30 | 11.92 | 20.24 | 1.15 | 2.60 | 0.9429 | 16.02 | 2.24 | -3.81 | -15.54 | -23.54 | 30.71 | -- |
| Catalyst Pharmaceuticals Inc | 534.65m | 197.35m | 2.64bn | 181.00 | 13.77 | 3.32 | 11.21 | 4.93 | 1.57 | 1.57 | 4.25 | 6.51 | 0.6874 | 3.74 | 8.12 | 2,953,845.00 | 25.37 | 24.62 | 28.93 | 28.82 | 86.11 | 85.77 | 36.91 | 31.73 | 5.96 | -- | 0.00 | 0.00 | 23.49 | 36.89 | 129.50 | 38.75 | 95.70 | -- |
| Amneal Pharmaceuticals Inc | 2.83bn | -13.05m | 2.64bn | 8.10k | -- | -- | 9.66 | 0.9325 | -0.042 | -0.042 | 8.97 | -0.4201 | 0.8298 | 3.06 | 3.98 | 349,405.70 | 0.9505 | -2.12 | 1.35 | -2.68 | 36.69 | 35.94 | 1.15 | -3.47 | 0.845 | 1.45 | 1.02 | -- | 16.73 | 11.43 | -39.16 | -- | -5.10 | -- |
| Mirum Pharmaceuticals Inc | 379.25m | -77.34m | 2.64bn | 334.00 | -- | 11.30 | -- | 6.96 | -1.61 | -1.61 | 7.90 | 4.72 | 0.5651 | 3.94 | 5.03 | 1,177,798.00 | -11.52 | -29.54 | -13.95 | -34.57 | 77.10 | -- | -20.39 | -92.71 | 3.04 | -66.48 | 0.5695 | -- | 80.76 | -- | 46.18 | -- | 136.96 | -- |
| Ultragenyx Pharmaceutical Inc | 590.69m | -549.58m | 2.76bn | 1.29k | -- | 19.03 | -- | 4.68 | -5.88 | -5.88 | 6.32 | 1.54 | 0.4511 | 2.14 | 5.93 | 456,483.00 | -41.97 | -33.04 | -52.98 | -38.84 | 85.13 | 91.29 | -93.04 | -127.45 | 2.24 | -- | 0.00 | -- | 29.01 | 40.12 | 6.17 | -- | -4.24 | -- |
| Prestige Consumer Healthcare Inc | 1.14bn | 214.61m | 3.76bn | 600.00 | 17.83 | 2.06 | 15.37 | 3.31 | 4.29 | 4.29 | 22.72 | 37.06 | 0.3386 | 3.51 | 6.13 | 1,896,270.00 | 6.39 | 4.13 | 6.61 | 4.30 | 55.76 | 56.31 | 18.86 | 13.13 | 2.82 | 7.33 | 0.3563 | 0.00 | 1.10 | 3.39 | 2.52 | 8.57 | -13.84 | -- |
| Perrigo Company PLC | 4.34bn | -164.70m | 3.77bn | 8.38k | -- | 0.8617 | 23.60 | 0.8692 | -1.20 | -1.31 | 31.53 | 31.81 | 0.425 | 2.42 | 5.56 | 517,388.70 | -1.61 | -0.7059 | -1.85 | -0.8082 | 36.38 | 34.96 | -3.80 | -1.76 | 1.28 | 2.17 | 0.4539 | -- | -6.06 | 2.48 | -3,552.27 | -- | -16.23 | 18.65 |
| PTC Therapeutics, Inc. | 1.77bn | 594.84m | 3.92bn | 939.00 | 7.61 | -- | 6.30 | 2.21 | 6.50 | 6.50 | 22.35 | -2.34 | 0.7976 | 2.15 | 8.69 | 1,887,921.00 | 26.76 | -26.68 | 36.33 | -34.84 | 96.87 | 93.49 | 33.55 | -74.67 | 3.85 | 5.13 | 1.08 | -- | -13.97 | 21.32 | 42.02 | -- | -13.92 | -- |
| Avidity Biosciences Inc | 8.93m | -369.22m | 4.05bn | 391.00 | -- | 3.04 | -- | 453.28 | -3.00 | -3.00 | 0.0732 | 11.03 | 0.0074 | -- | 0.4679 | 22,831.20 | -30.63 | -30.46 | -32.81 | -33.14 | -- | -- | -4,136.00 | -1,901.74 | -- | -- | 0.00 | -- | 13.99 | 36.27 | -51.87 | -- | 97.52 | -- |
| ADMA Biologics Inc | 459.38m | 206.77m | 4.46bn | 677.00 | 22.23 | 11.93 | 20.77 | 9.71 | 0.8401 | 0.8401 | 1.88 | 1.57 | 1.07 | 1.25 | 6.16 | 678,553.90 | 48.01 | -2.99 | 54.78 | -3.39 | 52.58 | 34.09 | 45.01 | -4.56 | 3.36 | 15.70 | 0.1626 | -- | 65.15 | 70.79 | 800.00 | -- | 17.60 | -- |
Data as of Jul 15 2025. Currency figures normalised to Perrigo Company PLC's reporting currency: US Dollar USD
52.26%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| T. Rowe Price Associates, Inc. (IM)as of 31 May 2025 | 14.23m | 10.43% |
| The Vanguard Group, Inc.as of 31 Mar 2025 | 13.70m | 10.05% |
| BlackRock Fund Advisorsas of 31 Mar 2025 | 11.81m | 8.65% |
| Dimensional Fund Advisors LPas of 31 Mar 2025 | 6.83m | 5.00% |
| SSgA Funds Management, Inc.as of 31 Mar 2025 | 6.70m | 4.91% |
| DePrince, Race & Zollo, Inc.as of 31 Mar 2025 | 4.57m | 3.35% |
| Neuberger Berman Investment Advisers LLCas of 31 Mar 2025 | 3.80m | 2.79% |
| Cooke & Bieler LPas of 31 Mar 2025 | 3.54m | 2.60% |
| Sound Shore Management, Inc.as of 31 Mar 2025 | 3.29m | 2.41% |
| ION Asset Management Ltd. (Israel)as of 31 Mar 2025 | 2.83m | 2.08% |
More ▼
Data from 31 Mar 2025 - 31 Mar 2025Source: FactSet Research Systems Inc.
